Cargando…

Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment

This phase I, dose‐escalation study evaluated the safety, preliminary efficacy and pharmacokinetics of nintedanib, a triple angiokinase inhibitor, in Japanese patients with advanced hepatocellular carcinoma and mild/moderate liver impairment. Thirty patients with unresectable hepatocellular carcinom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okusaka, Takuji, Otsuka, Taiga, Ueno, Hideki, Mitsunaga, Shuichi, Sugimoto, Rie, Muro, Kei, Saito, Isao, Tadayasu, Yusuke, Inoue, Kohei, Loembé, Arsene‐Bienvenu, Ikeda, Masafumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198968/ https://www.ncbi.nlm.nih.gov/pubmed/27627050 http://dx.doi.org/10.1111/cas.13077

Ejemplares similares

Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial
por: Terazawa, Tetsuji, et al.
Publicado: (2014)

Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
por: Sunakawa, Yu, et al.
Publicado: (2013)

Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
por: Sunakawa, Yu, et al.
Publicado: (2013)

Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future
por: Ikeda, Masafumi, et al.
Publicado: (2015)

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2014)

A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Sasaki, Mitsuhito, et al.
Publicado: (2021)

Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma
por: Shiba, Satoshi, et al.
Publicado: (2012)

Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2014)

Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study
por: Iizumi, Sakura, et al.
Publicado: (2019)

Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma
por: Hagihara, Atsushi, et al.
Publicado: (2014)

Immunotherapy for hepatocellular carcinoma: current status and future perspectives
por: Okusaka, Takuji, et al.
Publicado: (2018)

A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)

Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the Treatment
por: Suyama, Koichi, et al.
Publicado: (2013)

Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial
por: Furuse, Junji, et al.
Publicado: (2022)

Dose‐response Trial of Lactoferrin in Patients with Chronic Hepatitis C
por: Okada, Shuichi, et al.
Publicado: (2002)

Germline mutations in cancer-predisposition genes in patients with biliary tract cancer
por: Terashima, Takeshi, et al.
Publicado: (2019)

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma
por: Okusaka, Takuji, et al.
Publicado: (2023)

Comment on: Combination of immunosuppressive therapy and nintedanib improves capillaroscopic changes in systemic sclerosis–interstitial lung disease: a case report
por: Sugimoto, Tomohiro, et al.
Publicado: (2022)

Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives
por: Hijioka, Susumu, et al.
Publicado: (2021)

A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results
por: Eisen, T, et al.
Publicado: (2015)

A retrospective analysis of factors associated with selection of end-of-life care and actual place of death for patients with cancer
por: Kondo, Shunsuke, et al.
Publicado: (2014)

Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis
por: Imaoka, Hiroshi, et al.
Publicado: (2021)

Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial
por: Ito, Tetsuhide, et al.
Publicado: (2012)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019)

Bullous pemphigoid associated with nintedanib
por: Hasson, Amelia M., et al.
Publicado: (2019)

Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases
por: Ito, Yoko, et al.
Publicado: (2019)

Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer
por: Irisawa, Ai, et al.
Publicado: (2022)

A case of welder's pneumoconiosis treated with corticosteroid followed by nintedanib
por: Kaida, Hideyuki, et al.
Publicado: (2022)

Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy
por: Kondo, Shunsuke, et al.
Publicado: (2012)

Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma
por: Kondo, Shunsuke, et al.
Publicado: (2018)

Focus on Nintedanib in NSCLC and Other Tumors
por: Manzo, Anna, et al.
Publicado: (2016)

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
por: Marzin, Kristell, et al.
Publicado: (2017)

Nintedanib ameliorates animal model of dermatitis
por: Heo, Min-Jeong, et al.
Publicado: (2020)

Nintedanib-Induced Renal Thrombotic Microangiopathy
por: Fujita, Takeshi, et al.
Publicado: (2021)

Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
por: Nasser, Mouhamad, et al.
Publicado: (2021)

Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
por: Okusaka, Takuji, et al.
Publicado: (2015)

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Okusaka, Takuji, et al.
Publicado: (2014)

Remarkable response of non‐small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis
por: Kai, Yoshiro, et al.
Publicado: (2021)

Integrated communication support program for oncologists, caregivers and patients with rapidly progressing advanced cancer to promote patient-centered communication: J-SUPPORT 1904 study protocol for a randomised controlled trial
por: Fujimori, Maiko, et al.
Publicado: (2020)

First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jr2g2ip36dpr7vaocmi1gqt0qt